Xencor's Kidney Cancer Trial: Promising Early Results
Update: 2025-10-24
Description
Xencor stock leaps as early trial results show promise for advanced kidney cancer treatment! A bispecific antibody, XmAb eight nineteen, is showing tumor shrinkage in 25% of patients, with 70% experiencing disease control. With manageable side effects and plans for Phase Three trials in 2027, Xencor offers a beacon of hope for patients who have failed multiple treatments.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
